| NCT01491737 | A Study of Pertuzumab in Combination With Trastuzumab Plus an Aromatase Inhibitor in Participants With Metastatic Human Epidermal Growth Factor Receptor 2 (HER2)-Positive and Hormone Receptor-Positive Advanced Breast Cancer | |
| NCT02132949 | A Study Evaluating Pertuzumab (Perjeta) Combined With Trastuzumab (Herceptin) and Standard Anthracycline-based Chemotherapy in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Locally Advanced, Inflammatory, or Early-stage Breast Cancer | |
| NCT01937117 | Pertuzumab and Trastuzumab as Neoadjuvant Treatment in Patients With HER2-Positive Breast Cancer | |
| NCT00999804 | Extension Study of Lapatinib Plus Herceptin With or Without Endocrine Therapy | |
| NCT00003612 | Combination Chemotherapy and Trastuzumab in Treating Women With Metastatic Breast Cancer | |
| NCT00796978 | Trastuzumab in Treating Older Women With Early-Stage Breast Cancer | |
| NCT00470704 | Lapatinib in Combination With Trastuzumab in Patients With HER2-Positive, Metastatic Breast Cancer | |
| NCT00295893 | Combination Chemotherapy With or Without Trastuzumab in Treating Patients With Stage II or Stage III Breast Cancer | |
| NCT01796197 | Paclitaxel + Trastuzumab + Pertuzumab as Pre-Op for Inflammatory BrCa | |
| NCT01853748 | T-DM1 vs Paclitaxel/Trastuzumab for Breast (ATEMPT Trial) | |
| NCT02260531 | Cabozantinib +/- Trastuzumab In Breast Cancer Patients w/ Brain Metastases | |
| NCT00820872 | Docetaxel, Carboplatin, Trastuzumab, and Lapatinib in Treating Patients With Early Stage Breast Cancer | |
| NCT01625429 | Neoadjuvant Study of Nab-paclitaxel Plus Carboplatin in Breast Cancer | |
| NCT01745965 | A Prospective, Randomized Multicenter, Open-label Comparison of Preoperative Trastuzumab Emtansine (T-DM1) With or Without Standard Endocrine Therapy vs. Trastuzumab With Standard Endocrine Therapy Given for Twelve Weeks in Patients With Operable HER2+/HR+ Breast Cancer Within the ADAPT Protocol. | |